Bausch + Lomb Corporation (BLCO)
- Previous Close
13.86 - Open
14.04 - Bid 13.58 x 1400
- Ask 13.58 x 800
- Day's Range
13.53 - 14.35 - 52 Week Range
13.16 - 21.95 - Volume
523,318 - Avg. Volume
495,708 - Market Cap (intraday)
4.78B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.96 - Earnings Date Jul 31, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.97
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
www.bausch.com13,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: BLCO
Performance Overview: BLCO
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLCO
Valuation Measures
Market Cap
4.69B
Enterprise Value
8.96B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.11
Price/Book (mrq)
0.72
Enterprise Value/Revenue
2.08
Enterprise Value/EBITDA
16.85
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.81%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.31B
Net Income Avi to Common (ttm)
-337M
Diluted EPS (ttm)
-0.96
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
67.18%
Levered Free Cash Flow (ttm)
--
Research Analysis: BLCO
Company Insights: BLCO
BLCO does not have Company Insights